AI Insight
A new study demonstrates that administering semaglutide, a GLP-1 receptor agonist marketed as Wegovy or Ozempic, to elderly mice resulted in a notable extension of their lifespan. The research suggests that this weight-loss medication may have anti-aging properties beyond its known metabolic effects. The findings indicate potential longevity benefits from GLP-1 drugs in animal models.
Why it matters
If these results translate to humans, GLP-1 medications currently prescribed for weight loss and diabetes management could have broader applications in extending healthspan and lifespan. This research may reshape how we view these drugs, potentially opening new avenues for aging research and therapeutic interventions.
Understand the Science
Giving old mice semaglutide—commonly sold as Wegovy or Ozempic—extends their lifespan remarkably, a new study finds
Source: GLP-1 weight-loss medication could slow aging and extend lifespan